AstraZeneca, MSD’s Lynparza combo gets FDA nod for prostate cancer treatment

By NS Healthcare Staff Writer

02 Jun 23

Lynparza is a PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours…

Patient CarePharmaceuticals and Medicines

Novartis gets EC approval for Cosentyx for hidradenitis suppurativa

By NS Healthcare Staff Writer

02 Jun 23

The European approval is based on Phase 3 data from the SUNSHINE and SUNRISE trials which enrolled more…

Patient CarePharmaceuticals and Medicines

GRAIL and University of Oxford to Present Results From First Prospective Study of Multi-Cancer Early Detection in a Symptomatic Patient Population at 2023 ASCO Annual Meeting

By NS Healthcare Staff Writer

02 Jun 23

SYMPLIFY Results Demonstrate Strong Performance of GRAIL’s Multi-Cancer Early Detection Methylation-Based Platform in Individuals Presenting With Non-Specific Signs…

Patient CarePharmaceuticals and Medicines

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

By NS Healthcare Staff Writer

02 Jun 23

Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with…

Patient CarePharmaceuticals and Medicines

Sanofi’s frexalimab reduces disease activity in Phase 2 trial of MS patients

By NS Healthcare Staff Writer

01 Jun 23

In the trial, the number of new gadolinium-enhancing (GdE) T1-lesions was lowered by 89% and 79% in the…

Patient CarePharmaceuticals and Medicines

AbbVie’s upadacitinib meets primary, secondary endpoints in SLEek trial

By NS Healthcare Staff Writer

01 Jun 23

The phase 2 study was evaluating upadacitinib 30mg alone and in combination (ABBV-599 high dose) in systemic lupus…

Patient CarePharmaceuticals and Medicines

NIH finds genomic variant and ruxolitinib as treatment for disabling pansclerotic morphea

By NS Healthcare Staff Writer

01 Jun 23

The scientists found that the disorder has an overactive version of the STAT4 protein, which controls inflammation and…

Patient CarePharmaceuticals and Medicines

Pfizer’s marstacimab meets primary endpoints in Phase 3 trial

By NS Healthcare Staff Writer

31 May 23

In the late-stage trial, the prophylactic treatment with marstacimab showed a statistically significant and clinically relevant reduction in…

Patient CarePharmaceuticals and Medicines

Health Canada approves BeiGene’s BRUKINSA for chronic lymphocytic leukaemia

By NS Healthcare Staff Writer

31 May 23

Health Canada approved BRUKINSA based on positive efficacy results and a favourable safety profile from two global late-stage…

Patient CarePharmaceuticals and Medicines

MetrioPharm secures FDA Orphan Drug Designation for Duchenne muscular dystrophy treatment

By NS Healthcare Staff Writer

31 May 23

DMD is the most common form of muscular dystrophy and is a genetic disorder characterised by progressive muscle…

Pharmaceuticals and MedicinesPatient Care